Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 130

1.

Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: comparison, efficacy and safety.

Deacon CF, Holst JJ.

Expert Opin Pharmacother. 2013 Oct;14(15):2047-58. doi: 10.1517/14656566.2013.824966. Epub 2013 Aug 7. Review.

PMID:
23919507
[PubMed - indexed for MEDLINE]
2.

Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis.

Karagiannis T, Paschos P, Paletas K, Matthews DR, Tsapas A.

BMJ. 2012 Mar 12;344:e1369. doi: 10.1136/bmj.e1369.

PMID:
22411919
[PubMed - indexed for MEDLINE]
Free Article
3.

Efficacy and safety of dipeptidyl peptidase-4 inhibitors in combination with metformin.

Fass AD, Gershman JA.

Adv Ther. 2013 Apr;30(4):337-53. Review.

PMID:
23605247
[PubMed - indexed for MEDLINE]
4.

Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences.

Baetta R, Corsini A.

Drugs. 2011 Jul 30;71(11):1441-67. doi: 10.2165/11591400-000000000-00000. Review.

PMID:
21812507
[PubMed - indexed for MEDLINE]
5.

Clinical pharmacokinetics and pharmacodynamics of vildagliptin.

He YL.

Clin Pharmacokinet. 2012 Mar 1;51(3):147-62. doi: 10.2165/11598080-000000000-00000. Review.

PMID:
22339447
[PubMed - indexed for MEDLINE]
6.

DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials.

Scheen AJ.

Diabetes Metab. 2012 Apr;38(2):89-101. doi: 10.1016/j.diabet.2011.11.001. Epub 2011 Dec 22. Review.

PMID:
22197148
[PubMed - indexed for MEDLINE]
Free Article
7.

Incretin-based therapies for type 2 diabetes mellitus: a review of direct comparisons of efficacy, safety and patient satisfaction.

Russell S.

Int J Clin Pharm. 2013 Apr;35(2):159-72. doi: 10.1007/s11096-012-9729-9. Epub 2012 Dec 22. Review.

PMID:
23263796
[PubMed - indexed for MEDLINE]
8.

Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.

Waugh N, Cummins E, Royle P, Clar C, Marien M, Richter B, Philip S.

Health Technol Assess. 2010 Jul;14(36):1-248. doi: 10.3310/hta14360. Review.

PMID:
20646668
[PubMed - indexed for MEDLINE]
Free Article
9.

[New blood glucose-lowering drugs in type 2 diabetes: a review of the literature].

Kleefstra N, van Hateren KJ, Houweling ST, Verhoeven S, Kooy A, Goudswaard AN, Bilo HJ.

Ned Tijdschr Geneeskd. 2010;154:A886. Review. Dutch.

PMID:
20298625
[PubMed - indexed for MEDLINE]
10.

Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4).

Thornberry NA, Gallwitz B.

Best Pract Res Clin Endocrinol Metab. 2009 Aug;23(4):479-86. doi: 10.1016/j.beem.2009.03.004.

PMID:
19748065
[PubMed - indexed for MEDLINE]
11.

Differentiating among incretin therapies: a multiple-target approach to type 2 diabetes.

Cornell S.

J Clin Pharm Ther. 2012 Oct;37(5):510-24. doi: 10.1111/j.1365-2710.2012.01342.x. Epub 2012 Mar 21. Review.

PMID:
22436069
[PubMed - indexed for MEDLINE]
12.

Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus.

Richter B, Bandeira-Echtler E, Bergerhoff K, Lerch CL.

Cochrane Database Syst Rev. 2008 Apr 16;(2):CD006739. doi: 10.1002/14651858.CD006739.pub2. Review.

PMID:
18425967
[PubMed - indexed for MEDLINE]
13.

The entero-insular axis: implications for human metabolism.

Ranganath LR.

Clin Chem Lab Med. 2008;46(1):43-56. Review.

PMID:
18020966
[PubMed - indexed for MEDLINE]
14.

DPP-4 inhibitors in the treatment of type 2 diabetes.

Duez H, Cariou B, Staels B.

Biochem Pharmacol. 2012 Apr 1;83(7):823-32. doi: 10.1016/j.bcp.2011.11.028. Epub 2011 Dec 13.

PMID:
22172989
[PubMed - indexed for MEDLINE]
15.

Dipeptidyl peptidase-4 inhibitor ameliorates early renal injury through its anti-inflammatory action in a rat model of type 1 diabetes.

Kodera R, Shikata K, Takatsuka T, Oda K, Miyamoto S, Kajitani N, Hirota D, Ono T, Usui HK, Makino H.

Biochem Biophys Res Commun. 2014 Jan 17;443(3):828-33. doi: 10.1016/j.bbrc.2013.12.049. Epub 2013 Dec 14.

PMID:
24342619
[PubMed - indexed for MEDLINE]
16.

Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review.

Deacon CF.

Diabetes Obes Metab. 2011 Jan;13(1):7-18. doi: 10.1111/j.1463-1326.2010.01306.x. Review.

PMID:
21114598
[PubMed - indexed for MEDLINE]
17.

Reshaping diabetes care: the fundamental role of dipeptidyl peptidase-4 inhibitors and glucagon-like peptide-1 receptor agonists in clinical practice.

Umpierrez GE, Meneghini L.

Endocr Pract. 2013 Jul-Aug;19(4):718-28. doi: 10.4158/EP12292.RA. Review.

PMID:
23512382
[PubMed - indexed for MEDLINE]
18.

Tolerability of dipeptidyl peptidase-4 inhibitors: a review.

Richard KR, Shelburne JS, Kirk JK.

Clin Ther. 2011 Nov;33(11):1609-29. doi: 10.1016/j.clinthera.2011.09.028. Epub 2011 Nov 8. Review.

PMID:
22071236
[PubMed - indexed for MEDLINE]
19.

Second line therapy: type 2 diabetic subjects failing on metformin GLP-1/DPP-IV inhibitors versus sulphonylurea/insulin: for GLP-1/DPP-IV inhibitors.

Kumar A.

Diabetes Metab Res Rev. 2012 Dec;28 Suppl 2:21-5. doi: 10.1002/dmrr.2350. Review.

PMID:
23280862
[PubMed - indexed for MEDLINE]
20.

Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors: meta-analysis and systematic review.

Aroda VR, Henry RR, Han J, Huang W, DeYoung MB, Darsow T, Hoogwerf BJ.

Clin Ther. 2012 Jun;34(6):1247-1258.e22. doi: 10.1016/j.clinthera.2012.04.013. Epub 2012 May 18. Review. Erratum in: Clin Ther. 2014 Feb 1;36(2):307-8.

PMID:
22608780
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk